Zura Bio said its Phase 2 TibuSHIELD trial of tibulizumab (ZB-106) in 247 adults with moderate-to-severe hidradenitis suppurativa (HS) missed its primary endpoint at Week 16 for both tested doses.
Abscess and inflammatory nodule counts fell 56.0% with the 300 mg dose and 58.1% with 150 mg, versus 52.5% with placebo; the difference was not statistically significant. Key secondary measures, HiSCR50 and HiSCR75, were also missed.
Zura is discontinuing tibulizumab development for HS. The company says its studies in systemic sclerosis and polymyalgia rheumatica will continue.
The report described Zura shares as plunging more than 70% in premarket trading following the announcement, as investors reacted to the loss of the HS program.
Sources:
sec-gov-archives-edgar-data-1855644-000110465926124149-tm2629310d1-ex99-1-htm
Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
Zura Bio shares plunge after study setback derails HS ambitions
Why is Zura Bio stock collapsing today?
Why is Zura Bio stock collapsing today? By Investing.com
Zura Bio's tibulizumab misses Phase 2 primary goal
Zura Bio's tibulizumab fails Phase 2 HS trial, discontinues development
Zura Bio Shares Plunge 76% After Phase 2 Trial Failure | Grafa
Zura Bio's skin disease drug fails mid-stage trial
Zura Bio’s tibulizumab fails phase 2 trial for skin disease By Investing.com
Zura Bio's tibulizumab fails phase 2 trial for skin disease By Investing.com
Why Is Zura Bio (ZURA) Stock Down -72.37% Today? - tickeron.com